P54

Opoku-Darko, Michael; Yuen, C.; Grassi, Claudio; Gratton, Kathy; Bathe, Oliver F.

doi:10.1016/j.jss.2006.12.283

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TEM8/ANTXR1: A marker of hypoxia, vasculogenic mimicry, and mediator of metastasis TEM8/ANTXR1 is an integrin-like, transmembrane glycoprotein upregulated in a variety of cancer types, tumor associated stromal cells, and tumor-associated blood vessels (Yang et al, 2011;Evans et al, 2018) (Figure 1). TEM8/ ANTXR1 is upregulated in the presence of hypoxia (Opoku-Darko et al, 2007). TEM8/ANTXR1 is unique in its association with tumor vessels but not normal blood vessels (Chaudhary et al, 2012).…”

Section: Study Description Outcomesmentioning

confidence: 99%

Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics

Corbett

Hallenbeck²,

Rychahou

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Oncolytic viruses have made a significant inroad in cancer drug development. Numerous clinical trials are currently investigating oncolytic viruses both as single agents or in combination with various immunomodulators. Oncolytic viruses (OV) are an integral pillar of immuno-oncology and hold potential for not only delivering durable anti-tumor responses but also converting “cold” tumors to “hot” tumors. In this review we will discuss one such promising oncolytic virus called Seneca Valley Virus (SVV-001) and its therapeutic implications. SVV development has seen seismic evolution over the past decade and now boasts of being the only OV with a practically applicable biomarker for viral tropism. We discuss relevant preclinical and clinical data involving SVV and how bio-selecting for TEM8/ANTXR1, a negative tumor prognosticator can lead to first of its kind biomarker driven oncolytic viral cancer therapy.

show abstract

Section: Study Description Outcomesmentioning

confidence: 99%